Emmaus Life Sciences, Inc. (EMMA) intrinsic value & 10-year financials
Emmaus Life Sciences, Inc. (EMMA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 74.0% a year to $12.5M, with an average return on invested capital of 219.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.06
- Market cap
- $3.7M
- Revenue (FY2025)
- $12.5M
- Revenue growth (10-yr CAGR)
- 74.0%
- ROIC (10-yr avg)
- 219.9%
- Free cash flow (FY2025)
- -$12.0K
EMMA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $12.5M | -$7.5M | -$0.12 | -$12.0K | 1.9% | -0.7% |
| FY2024 | $16.7M | -$6.5M | -$0.10 | -$2.3M | -11.4% | 8.2% |
| FY2023 | $29.6M | -$3.7M | -$0.07 | -$1.5M | 12.0% | -33.1% |
| FY2022 | $18.4M | -$10.6M | -$0.21 | -$5.1M | -35.8% | 1037.2% |
| FY2021 | $20.6M | -$15.9M | -$0.32 | -$1.3M | -29.7% | -96.3% |
| FY2020 | $23.2M | $1.1M | — | -$2.5M | -0.1% | -3.3% |
| FY2019 | $22.8M | -$54.8M | — | -$4.6M | -19.8% | 50.8% |
| FY2018 | $16.5M | -$72.6M | — | -$5.7M | -51.4% | 98.5% |
| FY2017 | $128.5K | -$7.1M | — | -$4.9M | -5528.1% | -331.1% |
| FY2016 | $85.1K | -$5.9M | — | -$3.0M | -4426.3% | 1468.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Emmaus Life Sciences, Inc. is a consistent compounder, expanding top-line revenue at 74.0% annually over the past decade.
Emmaus Life Sciences, Inc. has historically struggled to out-earn its cost of capital, averaging just 4.6% ROIC.
Emmaus Life Sciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Emmaus Life Sciences, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-3.99 per share.